Advanced search
Publication Cover
Leukemia & Lymphoma Volume 32, 1998 - Issue 1-2
Submit an article Journal homepage
24
Views
20
CrossRef citations to date
0
Altmetric
Original Article

Anti-Tumour Activity of Bisphosphonates in Human Myeloma Cells

Claire M. Shipman Department of Medicine and Therapeutics, University of Aberdeen Medical School, Aberdeen, UK; Department of Human Metabolism and Clinical Biochemistry, University of Sheffield Medical School, Sheffield, UK
,
Michael J. Rogers Department of Medicine and Therapeutics, University of Aberdeen Medical School, Aberdeen, UK
,
Jane F. Apperley Department of Haematology, Royal Postgraduate Medical School, London, UK
,
R. Graham G. Russell Department of Medicine and Therapeutics, University of Aberdeen Medical School, Aberdeen, UK; Department of Human Metabolism and Clinical Biochemistry, University of Sheffield Medical School, Sheffield, UK
&
Peter I. Croucher Department of Medicine and Therapeutics, University of Aberdeen Medical School, Aberdeen, UK; Department of Human Metabolism and Clinical Biochemistry, University of Sheffield Medical School, Sheffield, UKCorrespondence[email protected]
Pages 129-138 | Received 04 Apr 1998, Published online: 01 Jul 2009

Citations (20)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Anders Ullén, Stephan Schwarz, Lena Lennartsson, Karl-Mikael Kälkner, Per Sandström, Fernanda Costa, Bo Lennernäs, Stig Linder & Sten Nilsson. (2009) Zoledronic acid induces caspase-dependent apoptosis in renal cancer cell lines. Scandinavian Journal of Urology and Nephrology 43:2, pages 98-103.
Read now
Anders Ullén, Lena Lennartsson, Ulrika Harmenberg, Marie Hjelm-Eriksson, Karl Mikael Kälkner, Bo Lennernäs & Sten Nilsson. (2005) Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid. Acta Oncologica 44:6, pages 644-650.
Read now

Articles from other publishers (18)

Tianhao Ren, Ju Huang, Wei Sun, Guangze Wang, Yuwen Wu, Zewei Jiang, Yingshuai Lv, Guang Wu, Jiawei Cao, Min Liu & Haihua Gu. (2023) Zoledronic acid induces ferroptosis by reducing ubiquinone and promoting HMOX1 expression in osteosarcoma cells. Frontiers in Pharmacology 13.
Crossref
Nicola Giuliani, Benedetta Dalla Palma & Marina Bolzoni. (2013) Bisphosphonates in Multiple Myeloma: Preclinical and Clinical Data. Clinical Reviews in Bone and Mineral Metabolism 11:3-4, pages 113-121.
Crossref
Hatice Demet Kiper, Burcin Tezcanli Kaymaz, Aysun Adan Gokbulut, Nur Selvi, Cigir Biray Avci, Buket Kosova, Guniz Iskender, Melis Kartal Yandim, Cumhur Gunduz, Fahri Sahin, Yusuf Baran & Guray Saydam. (2013) STAT pathway in the regulation of zoledronic acid-induced apoptosis in chronic myeloid leukemia cells. Biomedicine & Pharmacotherapy 67:6, pages 527-532.
Crossref
Antonietta R. Farina, Lucia Cappabianca, Natalia Di Ianni, Pierdomenico Ruggeri, Marzia Ragone, Stefania Merolle, Alberto Gulino & Andrew R. Mackay. (2012) Alendronate promotes plasmin‐mediated MMP‐9 inactivation by exposing cryptic plasmin degradation sites within the MMP‐9 catalytic domain. FEBS Letters 586:16, pages 2366-2374.
Crossref
Monica M. Reinholz, Shawn P. Zinnen, Amylou C. Dueck, David Dingli, Gregory G. Reinholz, Leslie A. Jonart, Kathleen A. Kitzmann, Amy K. Bruzek, Vivian Negron, Abdalla K. Abdalla, Bonnie K. Arendt, Anthony J. Croatt, Luis Sanchez-Perez, David P. Sebesta, Harri Lönnberg, Toshiyuki Yoneda, Karl A. Nath, Diane F. Jelinek, Stephen J. Russell, James N. Ingle, Thomas C. Spelsberg, Henry B.F. (Hal) Dixon, Alexander Karpeisky & Wilma L. Lingle. (2010) A promising approach for treatment of tumor-induced bone diseases: Utilizing bisphosphonate derivatives of nucleoside antimetabolites. Bone 47:1, pages 12-22.
Crossref
Andreas Guenther, Sharon Gordon, Markus Tiemann, Renate Burger, Frank Bakker, Jonathan R. Green, Wolfgang Baum, Anke J. Roelofs, Michael J. Rogers & Martin Gramatzki. (2009) The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation . International Journal of Cancer 126:1, pages 239-246.
Crossref
Victor H. Jimenez-Zepeda & Virginia J. Dominguez-Martinez. (2009) Plasma cell leukemia: a highly aggressive monoclonal gammopathy with a very poor prognosis. International Journal of Hematology 89:3, pages 259-268.
Crossref
Evan T. Keller, Jinlu Dai, June Escara-Wilke, Christopher L. Hall, Kathleen Ignatoski, Russell S. Taichman & Jill Keller. (2007) New trends in the treatment of bone metastasis. Journal of Cellular Biochemistry 102:5, pages 1095-1102.
Crossref
Evan T. Keller. 2007. Prostate Cancer. Prostate Cancer 175 191 .
Hardev Pandha, Lindsay Birchall, Brendan Meyer, Natalie Wilson, Kate Relph, Christopher Anderson & Kevin Harrington. (2006) Antitumor Effects of Aminobisphosphonates on Renal Cell Carcinoma Cell Lines. The Journal of Urology 176:5, pages 2255-2261.
Crossref
Savita Wakchoure, Melinda A. Merrell, Wayne Aldrich, Telisha Millender-Swain, Kevin W. Harris, Pierre Triozzi & Katri S. Selander. (2006) Bisphosphonates Inhibit the Growth of Mesothelioma Cells In vitro and In vivo . Clinical Cancer Research 12:9, pages 2862-2868.
Crossref
A. Ugur Ural, M. Ilker Yilmaz, Ferit Avcu, Aysel Pekel, Murat Zerman, Oral Nevruz, Ali Sengul & Atilla Yalcin. (2018) The Bisphosphonate Zoledronic Acid Induces Cytotoxicity in Human Myeloma Cell Lines with Enhancing Effects of Dexamethasone and Thalidomide. International Journal of Hematology 78:5, pages 443-449.
Crossref
Shozo Nishida, Yoshiki Fujii, Shohei Yoshioka, Sigeru Kikuichi, Masanobu Tsubaki & Kiyohiro Irimajiri. (2003) A new bisphosphonate, YM529 induces apoptosis in HL60 cells by decreasing phosphorylation of single survival signal ERK. Life Sciences 73:21, pages 2655-2664.
Crossref
Esa Jantunen. (2002) Bisphosphonate therapy in multiple myeloma: past, present, future. European Journal of Haematology 69:5-6, pages 257-264.
Crossref
Kenneth C. Anderson, Lawrence H. Boise, Robert Louie & Samuel Waxman. (2002) Arsenic Trioxide in Multiple Myeloma. The Cancer Journal 8:1, pages 12-25.
Crossref
Suzanne R. Hayman & Rafael Fonseca. (2001) Plasma cell leukemia. Current Treatment Options in Oncology 2:3, pages 205-216.
Crossref
Nikhil C. Munshi. (2001) Arsenic Trioxide: An Emerging Therapy for Multiple Myeloma. The Oncologist 6:S2, pages 17-21.
Crossref
Adina Schneider & Elizabeth Shane. 2001. Osteoporosis. Osteoporosis 303 326 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.